CEACAM1 and neoplasm: In a murine colorectal cancer model, co-blockade of CEACAM1 and TIM3 with monoclonal antibodies enhanced intrinsic anti-tumor responses, highlighting a potential target to enhance the efficacy of immunotherapies (61).